Alercell Inc — SEC Form D Filing

Alercell Inc filed an SEC Form D on October 19, 2026, reporting $35K raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 19, 2026
Amount reported
$35K
Round stage
Series A
Industry
Biotechnology
Website
https://www.alercell.com/

What the company does

Securities: Equity. Revenue: No Revenues. Exemption: Rule 506(b). Incorporated: MONTANA

Problem

Many cancers, including acute leukemia, are often diagnosed at advanced stages when five-year survival rates are low and aggressive treatment is required. There are no established general-population screening protocols for leukemia, leading to late detection and high mortality.

Solution

Alercell develops and provides a diagnostic platform, including assays like LENA Q51® and LENA S1®, that analyzes DNA methylation signatures in peripheral blood using AI to detect leukemia and lung cancer years before clinical symptoms appear.

Why now

Advances in AI and epigenetic research, combined with the availability of large patient datasets, now enable the development of highly accurate and early diagnostic tools that were previously impossible.

Verdict

Investors backed this round because the narrative positioned a high-sensitivity, AI-powered epigenetic early detection platform against intractable cancer mortality rates, specifically in leukemia. This cleared because of the *potential* for a paradigm shift in diagnostic timing, not because a clear path to widespread clinical adoption or reimbursement was established. The implicit bet was on a future where early, non-invasive detection could dramatically improve outcomes, while the limited upside stemmed from the long regulatory and commercialization cycles inherent in novel diagnostic tools, suggesting a protracted path to significant market penetration.

Source: SEC EDGAR Form D filing